EXAGEN INC. Net Fee Amt
EXAGEN INC. (XGN) had Net Fee Amt of $490.44 as of 2026-05-12, per its S-8 filed 2026-05-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-12
- 2026-05-12: Net Fee Amt $490.44.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-12 | $490.44 S-8 · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |